Author:
Kuo Tsun-Yung,Lin Meei-Yun,Coffman Robert L.,Campbell John D.,Traquina Paula,Lin Yi-Jiun,Liu Luke Tzu-Chi,Cheng Jinyi,Wu Yu-Chi,Wu Chung-Chin,Tang Wei-Hsuan,Huang Chung-Guei,Tsao Kuo-Chien,Chen Charles
Abstract
AbstractThe COVID-19 pandemic is a worldwide health emergency which calls for an unprecedented race for vaccines and treatment. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein, S-2P. To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of neutralizing antibodies in sera of immunized mice against pseudotyped lentivirus reporter or live wild-type SARS-CoV-2. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018 and alum as a candidate vaccine to prevent COVID-19 disease.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
2. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf. Dis. 20(5), 533–534 (2020).
3. Gates, B. Responding to Covid-19—A once-in-a-century pandemic?. N. Engl. J. Med. 382(18), 1677–1679 (2020).
4. Schäferhoff, M., Yamey, G. & McDade, K. Funding the development and manufacturing of COVID-19 vaccines: The need for global collective action. Brookings. https://www.brookings.edu/blog/future-development/2020/04/24/funding-the-development-and-manufacturing-of-covid-19-vaccines-the-need-for-global-collective-action/ Accessed 1 June 2020. (2020)
5. WHO R&D Blueprint. DRAFT Landscape of COVID-19 Candidate Vaccines—31 July 2020. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines (2020)
Cited by
141 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献